MTOR and endometrial carcinoma: mTOR inhibitors (temsirolimus, everolimus, and ridaforolimus) have been tested in phase I and II clinical trials for advanced and recurrent endometrial carcinomas with some promising clinical outcomes; however, response rates are not robust.